Yehuda Handelsman to Hypolipidemic Agents
This is a "connection" page, showing publications Yehuda Handelsman has written about Hypolipidemic Agents.
Connection Strength
2.611
-
Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis. J Clin Lipidol. 2025 May-Jun; 19(3):412-421.
Score: 0.925
-
Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II. Diabetes Obes Metab. 2017 07; 19(7):989-996.
Score: 0.542
-
TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS. Endocr Pract. 2017 Jan; 23(1):100-112.
Score: 0.526
-
Role of bile acid sequestrants in the treatment of type 2 diabetes. Diabetes Care. 2011 May; 34 Suppl 2:S244-50.
Score: 0.359
-
Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus? Expert Rev Clin Pharmacol. 2012 Jan; 5(1):43-54.
Score: 0.094
-
Bile acid sequestrants for lipid and glucose control. Curr Diab Rep. 2010 Feb; 10(1):70-7.
Score: 0.082
-
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. Endocr Pract. 2018 01; 24(1):91-120.
Score: 0.036
-
American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summary. Endocr Pract. 2012 Mar-Apr; 18(2):269-93.
Score: 0.024
-
American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2012 Mar-Apr; 18 Suppl 1:1-78.
Score: 0.024